title: Update on anti-tumor necrosis factor agents in Crohn disease.
abstract: Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.
authors.affiliation: Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA.
authors.forename: Siddharth
authors.initials: S
authors.lastname: Singh
authors.affiliation: Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA. Electronic address: Pardi.Darrell@mayo.edu.
authors.forename: Darrell S
authors.initials: DS
authors.lastname: Pardi
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D057915:Drug Substitution; D006760:Hospitalization; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011788:Quality of Life; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol
keywords: Adalimumab; Anti-tumor necrosis factor; Certolizumab pegol; Crohn disease; Infliximab